VERU INC. Logo

VERU INC.

Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.

VERU | US

Overview

Corporate Details

ISIN(s):
US92536C1036
LEI:
Country:
United States of America
Address:
2916 N. MIAMI AVENUE, 33127 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Veru Inc. is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for cardiometabolic and inflammatory diseases. The company's pipeline is primarily focused on enobosarm, an oral selective androgen receptor modulator (SARM) designed to preserve muscle in patients undergoing weight loss therapy with GLP-1 drugs, thereby promoting higher-quality weight loss. Veru is also advancing sabizabulin, a novel oral anti-inflammatory agent for the treatment of atherosclerotic coronary artery disease. In addition to its cardiometabolic focus, the company has also developed therapies for oncology and viral-induced acute respiratory distress syndrome (ARDS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all VERU INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VERU INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VERU INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore
950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America
PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America
PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea
296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America
PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America
PMN
Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX

Talk to a Data Expert

Have a question? We'll get back to you promptly.